A61K 9/1676
Having a drug-free core with discrete complete coating layer containing drug
Official title: {having a drug-free core with discrete complete coating layer containing drug (adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K9/141; with further drug-free outer coating A61K9/5078; drug conjugated to non-active particles A61K47/6921)}
A61K9/1676 (Having a drug-free core with discrete complete coating layer containing drug) appears on 716 US grants and 1,218 published applications in this corpus.
Search patents in A61K- Granted patents
- 716
- Published applications
- 1,218
- Assignees
- 517
- Inventors
- 1,841
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 2 | 0 |
| 1980 | 0 | 0 |
| 1981 | 1 | 0 |
| 1982 | 2 | 0 |
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 2 | 0 |
| 1989 | 1 | 0 |
| 1990 | 4 | 0 |
| 1991 | 5 | 0 |
| 1992 | 6 | 0 |
| 1993 | 3 | 0 |
| 1994 | 4 | 0 |
| 1995 | 6 | 0 |
| 1996 | 8 | 0 |
| 1997 | 11 | 0 |
| 1998 | 8 | 0 |
| 1999 | 11 | 0 |
| 2000 | 9 | 0 |
| 2001 | 16 | 3 |
| 2002 | 12 | 24 |
| 2003 | 18 | 33 |
| 2004 | 9 | 40 |
| 2005 | 6 | 46 |
| 2006 | 10 | 39 |
| 2007 | 1 | 42 |
| 2008 | 11 | 43 |
| 2009 | 7 | 51 |
| 2010 | 22 | 58 |
| 2011 | 17 | 63 |
| 2012 | 19 | 51 |
| 2013 | 24 | 55 |
| 2014 | 45 | 57 |
| 2015 | 35 | 73 |
| 2016 | 57 | 75 |
| 2017 | 35 | 51 |
| 2018 | 26 | 45 |
| 2019 | 41 | 61 |
| 2020 | 50 | 61 |
| 2021 | 39 | 50 |
| 2022 | 32 | 52 |
| 2023 | 22 | 40 |
| 2024 | 38 | 51 |
| 2025 | 23 | 30 |
| 2026 | 16 | 24 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics8 Sep 2026US 12,728,110 B2Flamel Ireland Limited
- Liquisolid pharmaceutical formulation and process for manufacturing8 Sep 2026US 12,728,134 B2Rheinische Friedrich-Wilhelms-Universität Bonn
- Coated granules produced by in-situ crosslinking process16 Jun 2026US 12,653,221 B2Danisco US Inc.
- Preparation of solid dosage forms comprising antibodies by solutions/suspension layering16 Jun 2026US 12,653,786 B2Tillotts Pharma AG
- Composition containing levamlodipine besylate hydrate and its preparation method9 Jun 2026US 12,648,937 B2Beijing Wuwei Erchuang Technology Co., Ltd.
- Solid oral dosage form comprising antibodies for sustained release in the lower gastrointestinal tract20 Aug 2026US 2026/0240774 A1Tillotts Pharma AG
- Glutathione-coated gold nanoparticles functionalized with lithium (lig-aunps) and uses thereof for the modulation of glycogen synthase kinase - 3 activity13 Aug 2026US 2026/0232592 A1Fondazione Policlinico Universitario Agostino Geme
- Pellet of dabigatran etexilate or pharmaceutically acceptable salt thereof6 Aug 2026US 2026/0224545 A1Bostal Drug Delivery Co., Ltd.
- Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof23 Jul 2026US 2026/0207534 A1Ensysce Biosciences Inc.
- Oral Brexanolone Compositions and Methods of Preparation and Use16 Jul 2026US 2026/0199372 A1Lipocine Inc.
Most cited
By later US patents
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions930US 6,248,363 B1Lipocine Inc. · 2001
- Method for producing microparticles loaded with proteins791US 7,335,401 B2Roche Diagnostic Operations, Inc. · 2008
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions684US 6,923,988 B2Lipocine Inc. · 2005
- Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions616US 6,569,463 B2Lipocine Inc. · 2003
- Cardiac drug delivery system404US 6,086,582 A2000